|
Lynparza, a cancer drug developed jointly with U.S.-based Merck,
was backed for standalone use or in combination with endocrine
therapy in adults with a form of genetically mutated early-stage
breast cancer.
The drug, which has received a similar recommendation in the
United States in March, is a key asset for AstraZeneca. It was
recommended in patients with low-to-normal levels of a protein
known as HER2 that is the target of several new therapies.
Enhertu, developed jointly with Japan's Daiichi Sankyo, was the
other drug that was endorsed by the European Medicines Agency
for treating an aggressive form of breast cancer characterised
by a high rate of HER2.
Enhertu is seen as a major growth driver for AstraZeneca, with
some analysts expecting peaks sales of $10 billion. The drug is
also expected to be cleared for patients with low levels of HER2
this month after the recent success of a trial.
(Reporting by Amna Karimi in Bengaluru; Editing by Rashmi Aich
and Anil D'Silva)
[© 2022 Thomson Reuters. All rights
reserved.] Copyright 2022 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|
